Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab combination therapy in head and neck squamous cell carcinoma
NCT04854499Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of magrolimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Gilead Sciences. Started Sep 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04854499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854499.